Opening book details…
Can I read Towards a Change in the Diagnostic Algorithm of Autism Spectrum Disorders: Evidence Supporting Whole Exome Sequencing as a First-Tier Test on EtoBox?
Towards a Change in the Diagnostic Algorithm of Autism Spectrum Disorders: Evidence Supporting Whole Exome Sequencing as a First-Tier Test by Arteche-López, Ana (author);Gómez Rodríguez, Maria José (author);Sánchez Calvin, Maria Teresa (author);Quesada-Espinosa, Juan Francisco (author);Lezana Rosales, Jose Miguel (author);Palma Milla, Carmen (author);Gómez-Manjón, Irene (author);Hidalgo Mayoral, Irene (author);Pérez de la Fuente, Rubén (author);Díaz de Bustamante, Arancha (author);Darnaude, María Teresa (author);Gil-Fournier, Belén (author);Ramiro León, Soraya (author);Ramos Gómez, Patricia (author);Sierra Tomillo, Olalla (author);Juárez Rufián, Alexandra (author);Arranz Cano, Maria Isabel (author);Villares Alonso, Rebeca (author);Morales-Pérez, Pablo (author);Segura-Tudela, Alejandro (author);Camacho, Ana (author);Nuñez, Noemí (author);Simón, Rogelio (author);Moreno-García, Marta (author);Alvarez-Mora, Maria Isabel (author) is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.
What is Towards a Change in the Diagnostic Algorithm of Autism Spectrum Disorders: Evidence Supporting Whole Exome Sequencing as a First-Tier Test about?
Autism spectrum disorder (ASD) is a prevalent and extremely heterogeneous neurodevelopmental disorder (NDD) with a strong genetic component. In recent years, the clinical relevance of de novo mutations to the aetiology of ASD has been demonstrated. Current guidelines recommend chromosomal microarray (CMA) and a __FMR1__ testing as first-tier tests, but there is increasing evidence that support the use of NGS for the diagnosis of NDDs. Specifically in ASD, it has not been extensively evaluated and, thus, we performed and compared the clinical utility of CMA, __FMR1__ testing, and/or whole exome sequencing (WES) in a cohort of 343 ASD patients. We achieved a global diagnostic rate of 12.8% (44/343), the majority of them being characterised by WES (33/44; 75%) compared to CMA (9/44; 20.4%) or __FMR1__ testing (2/44; 4.5%). Taking into account the age at which genetic testing was carried out, we identified a causal genetic alteration in 22.5% (37/164) of patients over 5 years old, but only in 3.9% (7/179) of patients under this age. Our data evidence the higher diagnostic power of WES compared to CMA in the study of ASD and support the implementation of WES as a first-tier test for the
Who reads Towards a Change in the Diagnostic Algorithm of Autism Spectrum Disorders: Evidence Supporting Whole Exome Sequencing as a First-Tier Test?
It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.
- Author
- Arteche-López, Ana (author);Gómez Rodríguez, Maria José (author);Sánchez Calvin, Maria Teresa (author);Quesada-Espinosa, Juan Francisco (author);Lezana Rosales, Jose Miguel (author);Palma Milla, Carmen (author);Gómez-Manjón, Irene (author);Hidalgo Mayoral, Irene (author);Pérez de la Fuente, Rubén (author);Díaz de Bustamante, Arancha (author);Darnaude, María Teresa (author);Gil-Fournier, Belén (author);Ramiro León, Soraya (author);Ramos Gómez, Patricia (author);Sierra Tomillo, Olalla (author);Juárez Rufián, Alexandra (author);Arranz Cano, Maria Isabel (author);Villares Alonso, Rebeca (author);Morales-Pérez, Pablo (author);Segura-Tudela, Alejandro (author);Camacho, Ana (author);Nuñez, Noemí (author);Simón, Rogelio (author);Moreno-García, Marta (author);Alvarez-Mora, Maria Isabel (author)
- Publisher
- MDPI AG
- Published
- 2021
- Language
- EN
- Field
- Biochemistry, Genetics and Molecular Biology (Life Sciences)